Get Ready for Hep C Meds Mavyret and Vosevi

October 2017

You'll see big changes in treating hepatitis C due to the new oral antivirals, Mavyret and Vosevi.

Expect to get more involved in managing hep C...just like you're managing heart disease, diabetes, etc. The newer hep C meds are easier to initiate, require less monitoring, and are better tolerated.

Mavyret (MAV-ih-reht, glecaprevir/pibrentasvir) will be another game changer. It's the first hep C med approved for just 8 weeks for initial therapy of all genotypes for most patients without cirrhosis.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Beta-Blockers Switch Patients From Atenolol to a Better Beta-Blocker
Influenza Answer Your Patients' Questions About 2017-2018 Influenza Vaccination
Opioids Be Aware of New Limits on First-Time Opioid Prescriptions
Pediatrics Emphasize Lifestyle Changes First for Most Hypertensive Kids
Stroke Consider Pros and Cons of Switching Antiplatelets After a Breakthrough Stroke
Psychiatry Recommend Psychotherapy Before Meds for Post-Traumatic Stress Disorder (PTSD)
Inhalers Think of ArmonAir as Similar to Flovent
Hair Loss Explain What Works and Doesn't Work for Hair Loss in Women
Simplify Statistical Terms When Explaining Treatment Pros and Cons
Hepatitis C Get Ready for Hep C Meds Mavyret and Vosevi
Bowel Preps Help Patients With Bowel Preps for Colorectal Cancer Screening
Smoking Cessation Address Concerns About Nicotine Replacement Therapy

Get Ready for Hep C Meds Mavyret and Vosevi

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents